MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Omeros Corporation ROE Ratio 2011-2025 | OMER
Annual ROE Ratio Omeros Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 85.87 | 471.57 | 55.34 | 816.8 | 114.33 | 77.5 | 126.56 | 1900.53 | 178.24 | 286.25 | 172.72 | 216.47 | 588.64 | 513.97 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1900.53 | 55.34 | 400.34 |
Quarterly ROE Ratio Omeros Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 61.71 | 68.6 | 102.46 | 118.01 | 388.59 | 638.25 | 411.44 | 27.39 | 65.08 | -167.8 | 108.37 | 802.3 | 810.94 | 781.89 | 699.17 | 36.06 | 66.93 | 90.14 | 106.1 | 114.33 | 110.27 | 93.52 | 79.21 | 77.5 | 74.19 | 98.5 | 118.88 | 126.56 | 691.23 | 917.7 | 1394.33 | 3265.53 | 2729.79 | 2501.19 | 2169.04 | 89.71 | 112.86 | 151.51 | 36.97 | 286.25 | 259.24 | 226.27 | 204.87 | 172.72 | 134.2 | 166.68 | 198.43 | 216.47 | 324.85 | 452.69 | 509.5 | 588.64 | 653.89 | 567.86 | 532.38 | 513.97 | 117.25 | 95.26 | 117.79 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3265.53 | -167.8 | 449.28 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
-68.71 | $ 4.85 | 2.87 % | $ 805 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-84.9 | $ 3.21 | -1.23 % | $ 248 M |  USA |
 |
AlloVir
ALVR
|
-51.87 | - | 4.14 % | $ 49.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
-507.47 | $ 1.06 | -6.64 % | $ 293 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-43.41 | $ 215.41 | -2.27 % | $ 5 B |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
-36.22 | $ 3.15 | -3.85 % | $ 7.58 B |  Australia |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
BioVie
BIVI
|
-92.27 | $ 1.43 | -1.39 % | $ 2.11 M | USA |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-288.19 | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
1.11 | $ 94.02 | -0.84 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-40.17 | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.19 | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
21.78 | $ 26.2 | 3.68 % | $ 1.27 B | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
-38.95 | $ 9.59 | 0.31 % | $ 141 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-144.96 | $ 0.27 | -6.08 % | $ 588 M |  Israel |
 |
Arena Pharmaceuticals
ARNA
|
-91.56 | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
-531.22 | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
Catalyst Biosciences
CBIO
|
540.06 | $ 13.48 | -4.36 % | $ 887 M | USA |
 |
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
12.83 | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
16.2 | $ 549.1 | -2.69 % | $ 41.6 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-71.51 | $ 2.4 | 4.34 % | $ 15.1 M | USA |
 |
AstraZeneca PLC
AZN
|
20.44 | $ 91.04 | 1.35 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
-57.34 | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
10.1 | $ 8.87 | -1.55 % | $ 1.45 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
-19.35 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
114.5 | $ 11.23 | -2.69 % | $ 726 M | USA |
 |
Biogen
BIIB
|
9.76 | $ 174.94 | 0.48 % | $ 25.5 B | USA |
 |
Abeona Therapeutics
ABEO
|
-365.49 | $ 5.07 | -5.5 % | $ 108 M | USA |
 |
Celldex Therapeutics
CLDX
|
-21.13 | $ 27.11 | -1.47 % | $ 1.75 M | USA |
 |
ADiTx Therapeutics
ADTX
|
-8126.35 | $ 1.66 | -25.84 % | $ 21.9 K | USA |
 |
Cellectar Biosciences
CLRB
|
282.15 | $ 3.36 | -7.32 % | $ 41.1 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-1239.35 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-69.02 | - | -7.31 % | $ 87 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Завод ДИОД
DIOD
|
3.1 | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
-51.75 | - | - | - | Russia |